
|Articles|May 29, 2020
ASCRS 2020: Clinical trial results of KP1-121 0.25% for dry eye treatment
Author(s)Alex Delaney-Gesing
Advertisement
Edward Holland, MD, director of Cornea Services at Cincinnati Eye Institute, speaks with Ophthalmology Times' David Hutton on the results of a clinical trial using KP1-121 0.25% (loteprednol etabonate) for dry eye treatment during the 2020 ASCRS virtual meeting.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Nanoscope Therapeutics releases positive long-term safety results from EXTEND study
2
Avisi Technologies releases positive 12-month data from VITA Trial
3
Ocular Therapeutix reaches target enrollment of 555 patients in SOL-R trial
4
Selecting Anti-VEGF Therapies in Retinal Vascular Disease Management
5


















































.png)


